New research suggests that certain diabetes medications, specifically GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), may help prevent the worsening of anxiety and depression in patients with type 2 diabetes. The findings, published in The Lancet Psychiatry, analyzed health records of nearly 95,000 individuals in Sweden between 2009 and 2022, comparing mental health outcomes when they were on GLP-1 medications versus when they were not.
Mental Health Benefits Observed
The study revealed significant reductions in the risk of worsening mental illness with semaglutide and, to a lesser extent, liraglutide (Saxenda). Semaglutide was linked to a 42% lower risk of overall mental health decline, including a 44% reduction in worsening depression, a 38% decrease in worsening anxiety, and a 47% lower risk of worsening substance use disorders. Other GLP-1 drugs, such as exenatide and dulaglutide, did not demonstrate the same protective effect.
This is important because type 2 diabetes already doubles the risk of depression compared to the general population. The fact that some GLP-1 agonists appear to mitigate this risk is a notable finding; it suggests a potential dual benefit for patients managing both chronic physical and mental health conditions. Researchers theorize that improvements in body image, better blood sugar control, or even direct neurobiological mechanisms involving the brain’s reward system may play a role.
Caution Advised
Experts urge caution in interpreting these results. Prof. David Nutt of Imperial College London notes that improved physical health often leads to improved mental health, and relying solely on GLP-1 agonists for mental health treatment is unlikely to be effective. Prof. Eduard Vieta of the University of Barcelona echoes this sentiment, stating that the findings are reassuring regarding psychiatric safety but do not yet prove a direct therapeutic effect on depression or anxiety.
Pregnancy Risks Highlighted in Parallel Study
Crucially, a separate study also revealed significant risks associated with GLP-1 use during pregnancy. Analyzing nearly 500,000 Danish women, researchers found that inadvertent exposure to semaglutide or liraglutide in early pregnancy increased the risk of preterm birth by 84% (semaglutide) and 70% (liraglutide) relative to those not on the medications. The increased absolute risk of preterm birth was approximately 11% with semaglutide and 9% with liraglutide. This risk was observed in women using the drugs for diabetes treatment but not for weight loss.
“These findings underscore the importance of carefully weighing the potential benefits of GLP-1 agonists against their known risks, particularly for women of childbearing potential.”
These findings highlight the need for cautious clinical decision-making, especially considering the rising popularity of these drugs for off-label weight loss. The potential to stabilize mental health in some patients must be balanced against the clear risks of adverse pregnancy outcomes if used unknowingly during conception.
